NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or
the “Company”), a late-stage, clinical biopharmaceutical company
developing oral, non-statin medicines for patients at risk of
cardiovascular disease (“CVD”) with elevated of low-density
lipoprotein cholesterol (“LDL-C”), for whom existing therapies are
not sufficiently effective or well-tolerated, today announced
financial results for the three and six months ended June 30,
2024.
“I am extremely pleased with our execution over the first half
of 2024 and continue to be motivated by the team’s relentless
commitment to unlocking the value of obicetrapib. We were thrilled
to recently announce positive and statistically significant topline
data from the pivotal Phase 3 BROOKLYN trial, which targeted
heterozygous familial hypercholesterolemia (“HeFH”), a historically
difficult-to-treat patient population, and underscores
obicetrapib’s potential to address the significant unmet need for
lipid lowering therapies,” said Michael Davidson, M.D., Chief
Executive Officer of NewAmsterdam. “Results from BROOKLYN achieved
LDL-C lowering consistent with our phase 2 studies, along with a
safety profile comparable to placebo, and with over half of
patients on obicetrapib achieving the LDL-C guideline directed
treatment goal of less than 70 mg/dl, we believe obicetrapib has
potential to improve patient care for those living with
dyslipidemia.”
"In addition, we recently hosted an R&D Day event where we
detailed the differentiated target product profile of obicetrapib,
discussed our commercial strategy, and unveiled REMBRANDT, a Phase
3 clinical study evaluating the fixed-dose combination (“FDC”) of
obicetrapib and ezetimibe on coronary atherosclerotic plaque
buildup in adults with or at high risk of atherosclerotic
cardiovascular disease (“ASCVD”),” Dr. Davidson continued.
“Supported by our recently issued composition of matter patent,
which extends patent protection in the US for obicetrapib into
2043, and $430.7 million of cash, we are advancing our mission from
a position of strength. Looking at the second half and beyond, we
are eager to build on the results of BROOKLYN with topline data
from BROADWAY and TANDEM expected in the fourth quarter of 2024 and
first quarter of 2025, respectively, while concurrently advancing
our PREVAIL cardiovascular outcomes trial (“CVOT”).”
Clinical Development Updates
NewAmsterdam is developing obicetrapib, an oral, low-dose and
once-daily cholesteryl ester transfer protein (“CETP”) inhibitor,
as the preferred LDL-C lowering therapy to be used in patients at
risk of CVD for whom existing therapies are not sufficiently
effective or well-tolerated.
- In July 2024, NewAmsterdam announced positive topline data from
the Phase 3 BROOKLYN clinical trial evaluating obicetrapib in
patients with HeFH.
- The BROOKLYN trial met its primary endpoint, with the
obicetrapib arm achieving an LS mean reduction of 36.3% (p <
0.0001) compared to placebo at day 84, which was sustained at day
365 with an LS mean LDL-C reduction of 41.5% (p < 0.0001). The
observed changes in other biomarkers, including high-density
lipoprotein cholesterol (“HDL-C”), non-HDL-C, lipoprotein(a)
(“Lp(a)”), and apolipoprotein B (“ApoB”), met statistical
significance and were consistent with data reported from the
Company’s prior clinical trials.
- In the trial, obicetrapib was observed to be well-tolerated,
with safety results comparable to placebo and no increase in blood
pressure, nor any difference from placebo in liver enzymes, hs-CRP,
or renal function.
- NewAmsterdam plans to present full results from BROOKLYN at an
upcoming medical conference and to publish the data in a major
medical journal.
- In July 2024, NewAmsterdam completed patient enrollment in the
pivotal Phase 3 TANDEM clinical trial evaluating the FDC of
obicetrapib plus ezetimibe in adult patients with HeFH and/or ASCVD
or multiple risk factors for ASCVD.
- In May and June 2024, respectively, NewAmsterdam presented new
clinical and preclinical data highlighting the potential for
obicetrapib as a novel, oral, low-dose therapy for
hypercholesterolemia, at the European Atherosclerosis Society (EAS)
92nd Congress and National Lipid Association (NLA) 2024 Scientific
Sessions.
- In May 2024, NewAmsterdam announced the initiation of
REMBRANDT, a Phase 3 clinical trial evaluating the FDC of
obicetrapib and ezetimibe against placebo on coronary
atherosclerotic plaque characteristics in adults with or at
high-risk for ASCVD.
Corporate Updates
- In July 2024, NewAmsterdam appointed Mark C. McKenna and Wouter
Joustra to its Board of Directors and announced the departure of
Sander Slootweg from its Board of Directors.
- In June 2024, NewAmsterdam announced the United States Patent
and Trademark Office (“USPTO”) issued U.S. Patent No. 12,006,305,
titled “Salts of Obicetrapib and Processes for their Manufacture
and Intermediates Thereof.” The patent contains claims covering
amorphous obicetrapib hemicalcium, the solid form that will be used
in the Company’s products and will be listed in the FDA’s “Orange
Book” as a drug substance patent, if approved. The issuance of this
composition of matter patent provides intellectual property
protection for obicetrapib until July 2043.
- In May 2024, NewAmsterdam hosted an R&D Day event featuring
presentations from Company management and key opinion leader
cardiovascular disease specialists to discuss obicetrapib’s
clinical development path, NewAmsterdam’s commercial readiness and
strategy, and the cardiovascular disease landscape and
opportunities for innovative new products. An archived replay of
the event is available on the Investor Relations page of the
NewAmsterdam website at ir.newamsterdampharma.com.
Upcoming Potential Milestones
NewAmsterdam’s global, pivotal Phase 3 clinical development
program consists of four studies in over 12,250 patients, three for
obicetrapib monotherapy and one for a FDC of obicetrapib and
ezetimibe. NewAmsterdam currently expects to achieve the following
upcoming milestones:
- Announce full data from Phase 3 BROOKLYN trial for obicetrapib
monotherapy at an upcoming medical conference and publish the data
in a major medical journal.
- Announce topline data from the Phase 3 BROADWAY trial for
obicetrapib monotherapy in the fourth quarter of 2024. BROADWAY is
evaluating obicetrapib in adult patients with HeFH and/or
established ASCVD, whose LDL-C is not adequately controlled,
despite being on maximally tolerated lipid-lowering therapy.
- Announce topline data from the Phase 3 TANDEM trial evaluating
a FDC of obicetrapib and ezetimibe in the first quarter of
2025.
Second Quarter Financial Results
- Cash Position: As of June 30, 2024,
NewAmsterdam recorded cash of $430.7 million, compared to $340.5
million as of December 31, 2023. The increase in cash is primarily
driven by the proceeds of the follow-on offering and warrant
exercises partially offset by cash outflows related to research and
development costs as the Company continues development of
obicetrapib and increased spending on selling, general and
administrative expenses to support the Company’s growing
organization.
- Revenue: NewAmsterdam recognized $2.3 million
in revenue for the three months ended June 30, 2024, compared
to $1.7 million in the same period in 2023. This increase is due to
an increase in the amount of previously deferred revenue which was
recognized as revenue in the current period.
- Research and Development (“R&D”) Expenses:
R&D expenses were $38.4 million for the three months ended
June 30, 2024, compared to $34.3 million for the same period
in 2023. This increase was primarily due to clinical expenses
related to the Company’s ongoing Phase 3 clinical trials.
- Selling, General and Administrative (“SG&A”)
Expenses: SG&A expenses were $16.5 million in three
months ended June 30, 2024, compared to $9.9 million for the
same period in 2023. This increase was primarily due to an increase
in personnel costs related to expansion of the team to support the
growth of the organization and investments in capabilities to
support the Company’s planned commercial launch of obicetrapib, if
approved.
- Net loss: Net loss for the three months ended
June 30, 2024 was $39.0 million, or $0.41 per diluted share,
compared to net loss of $38.3 million, or $0.47 per diluted share,
for the same period in 2023.
About Obicetrapib
Obicetrapib is a novel, oral, low-dose CETP inhibitor that
NewAmsterdam is developing to overcome the limitations of current
LDL-lowering treatments. In each of the Company’s Phase 2 trials,
ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3
BROOKLYN trial, evaluating obicetrapib as monotherapy or
combination therapy, the Company observed statistically significant
LDL-lowering combined with a side effect profile similar to that of
placebo. The Company is conducting an additional Phase 3 pivotal
trial BROADWAY, to evaluate obicetrapib as a monotherapy used as an
adjunct to maximally tolerated lipid-lowering therapies to provide
additional LDL-lowering for CVD patients, and TANDEM, to evaluate
obicetrapib and ezetimibe as a fixed-dose combination. The Company
began enrolling patients in BROADWAY in January 2022 and in TANDEM
in March 2024; completing enrollment of BROADWAY in July 2023, and
TANDEM in July 2024. The Company also commenced the Phase 3 PREVAIL
cardiovascular outcomes trial in March 2022, which is designed to
assess the potential of obicetrapib to reduce occurrences of major
adverse cardiovascular events, including cardiovascular death,
non-fatal myocardial infarction, non-fatal stroke and non-elective
coronary revascularization. NewAmsterdam completed enrollment of
PREVAIL in April 2024 and randomized over 9,500 patients.
Commercialization rights of obicetrapib in Europe, either as a
monotherapy or as part of a fixed dose combination with ezetimibe,
for cardiovascular diseases have been exclusively granted to the
Menarini Group, an Italy-based, leading international
pharmaceutical and diagnostics company.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage
biopharmaceutical company whose mission is to improve patient care
in populations with metabolic diseases where currently approved
therapies have not been adequate or well tolerated. We seek to fill
a significant unmet need for a safe, well-tolerated and convenient
LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is
investigating obicetrapib, an oral, low-dose and once-daily CETP
inhibitor, alone or as a fixed-dose combination with ezetimibe, as
LDL-C lowering therapies to be used as an adjunct to statin therapy
for patients at risk of CVD with elevated LDL-C, for whom existing
therapies are not sufficiently effective or well tolerated.
Forward-Looking Statements
Certain statements included in this document that are not
historical facts are forward-looking statements for purposes of the
safe harbor provisions under the United States Private Securities
Litigation Reform Act of 1995. Forward-looking statements generally
are accompanied by words such as “believe,” “may,” “will,”
“estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,”
“would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,”
“outlook” and similar expressions that predict or indicate future
events or trends or that are not statements of historical matters.
These forward-looking statements include, but are not limited to,
statements regarding the Company’s intellectual property and its
ability to enforce, and sufficiency of, its patents, the
Company’s business and strategic plans, the Company’s commercial
opportunity, the therapeutic and curative potential of the
Company’s product candidate, the Company’s clinical trials and the
timing for enrolling patients, the timing and forums for announcing
data, the achievement and timing of regulatory approvals, and plans
for commercialization. These statements are based on various
assumptions, whether or not identified in this document, and on the
current expectations of the Company’s management and are not
predictions of actual performance. These forward-looking statements
are provided for illustrative purposes only and are not intended to
serve as and must not be relied on as a guarantee, an assurance, a
prediction, or a definitive statement of fact or probability.
Actual events and circumstances are difficult or impossible to
predict and may differ from assumptions. Many actual events and
circumstances are beyond the control of the Company. These
forward-looking statements are subject to a number of risks and
uncertainties, including changes in domestic and foreign business,
market, financial, political, and legal conditions; risks related
to the approval of the Company’s product candidate and the timing
of expected regulatory and business milestones, including potential
commercialization; ability to negotiate definitive contractual
arrangements with potential customers; the impact of competitive
product candidates; ability to obtain sufficient supply of
materials; global economic and political conditions, including the
Russia-Ukraine and Israel-Hamas conflict; the effects of
competition on the Company’s future business; and those factors
described in the Company’s public filings with the Securities
Exchange Commission. Additional risks related to the Company’s
business include, but are not limited to: uncertainty regarding
outcomes of the Company’s ongoing clinical trials, particularly as
they relate to regulatory review and potential approval for its
product candidate; risks associated with the Company’s efforts to
commercialize a product candidate; the Company’s ability to
negotiate and enter into definitive agreements on favorable terms,
if at all; the impact of competing product candidates on the
Company’s business; intellectual property related claims; the
Company’s ability to attract and retain qualified personnel;
ability to continue to source the raw materials for its product
candidate. If any of these risks materialize or the Company’s
assumptions prove incorrect, actual results could differ materially
from the results implied by these forward-looking statements. There
may be additional risks that the Company does not presently know or
that the Company currently believes are immaterial that could also
cause actual results to differ from those contained in the
forward-looking statements. In addition, forward-looking statements
reflect the Company’s expectations, plans, or forecasts of future
events and views as of the date of this document and are qualified
in their entirety by reference to the cautionary statements herein.
The Company anticipates that subsequent events and developments may
cause the Company’s assessments to change. These forward-looking
statements should not be relied upon as representing the Company’s
assessment as of any date subsequent to the date of this
communication. Accordingly, undue reliance should not be placed
upon the forward-looking statements. Neither the Company nor any of
its affiliates undertakes any obligation to update these
forward-looking statements, except as may be required by law.
Company ContactMatthew PhilippeP:
1-917-882-7512matthew.philippe@newamsterdampharma.com
Media ContactSpectrum Science on behalf of
NewAmsterdamBryan BlatsteinP:
1-917-714-2609bblatstein@spectrumscience.com
Investor ContactPrecision AQ on behalf of
NewAmsterdamAustin MurtaghP:
1-212-698-8696austin.murtagh@precisionaq.com
Financial Tables
|
|
|
|
|
|
NewAmsterdam
Pharma Company N.V.Condensed Consolidated Balance
Sheets(Unaudited) |
|
|
June 30, 2024 |
|
|
December 31, 2023 |
|
(In thousands of USD) |
|
|
|
|
|
Assets |
|
Current assets: |
|
|
|
|
|
Cash |
|
430,708 |
|
|
|
340,450 |
|
Prepayments and other receivables |
|
14,644 |
|
|
|
6,341 |
|
Total current assets |
|
445,352 |
|
|
|
346,791 |
|
Property, plant and equipment,
net |
|
234 |
|
|
|
46 |
|
Operating right of use
asset |
|
554 |
|
|
|
55 |
|
Intangible assets |
|
542 |
|
|
|
170 |
|
Long term prepaid
expenses |
|
8 |
|
|
|
35 |
|
Total assets |
|
446,690 |
|
|
|
347,097 |
|
Liabilities and
Shareholders' Equity |
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
Accounts payable |
|
5,275 |
|
|
|
16,923 |
|
Accrued expenses and other current liabilities |
|
10,194 |
|
|
|
11,398 |
|
Deferred revenue, current |
|
6,059 |
|
|
|
8,942 |
|
Lease liability, current |
|
234 |
|
|
|
60 |
|
Derivative warrant liabilities |
|
23,545 |
|
|
|
12,574 |
|
Total current liabilities |
|
45,307 |
|
|
|
49,897 |
|
Deferred revenue, net of
current portion |
|
222 |
|
|
|
1,019 |
|
Lease liability, net of
current portion |
|
328 |
|
|
|
- |
|
Derivative earnout
liability |
|
13,394 |
|
|
|
7,788 |
|
Total liabilities |
|
59,251 |
|
|
|
58,704 |
|
Commitments and contingencies
(Note 10) |
|
|
|
|
|
Shareholders' Equity
(deficit): |
|
|
|
|
|
Ordinary shares, €0.12 par value; 400,000,000 shares authorized;
90,015,357 and 82,469,768 shares issued and outstanding as at June
30, 2024 and December 31, 2023, respectively |
|
11,151 |
|
|
|
10,173 |
|
Additional paid-in capital |
|
821,613 |
|
|
|
590,771 |
|
Accumulated loss |
|
(449,747 |
) |
|
|
(316,973 |
) |
Accumulated other comprehensive income |
|
4,422 |
|
|
|
4,422 |
|
Total shareholders' equity |
|
387,439 |
|
|
|
288,393 |
|
Total liabilities and
shareholders' equity |
|
446,690 |
|
|
|
347,097 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NewAmsterdam Pharma Company N.V.Condensed
Consolidated Statements of Operations and Comprehensive Income
(Loss)(Unaudited) |
|
|
For the three months ended June 30, |
|
|
For the six months ended June 30, |
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
(In thousands of USD, except
per share amounts) |
|
|
|
|
|
|
|
|
|
|
|
Revenue |
|
2,279 |
|
|
|
1,717 |
|
|
|
3,680 |
|
|
|
10,346 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses |
|
38,379 |
|
|
|
34,341 |
|
|
|
80,809 |
|
|
|
74,761 |
|
Selling, general and administrative expenses |
|
16,475 |
|
|
|
9,858 |
|
|
|
30,928 |
|
|
|
17,920 |
|
Total operating expenses |
|
54,854 |
|
|
|
44,199 |
|
|
|
111,737 |
|
|
|
92,681 |
|
Operating loss |
|
(52,575 |
) |
|
|
(42,482 |
) |
|
|
(108,057 |
) |
|
|
(82,335 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
4,870 |
|
|
|
4,613 |
|
|
|
7,953 |
|
|
|
5,556 |
|
Fair value change – earnout and warrants |
|
9,692 |
|
|
|
(350 |
) |
|
|
(29,258 |
) |
|
|
(6,525 |
) |
Foreign exchange gains/(losses) |
|
(994 |
) |
|
|
(72 |
) |
|
|
(3,412 |
) |
|
|
2,995 |
|
Loss before tax |
|
(39,007 |
) |
|
|
(38,291 |
) |
|
|
(132,774 |
) |
|
|
(80,309 |
) |
Income tax expense |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Loss and comprehensive loss
for the period |
|
(39,007 |
) |
|
|
(38,291 |
) |
|
|
(132,774 |
) |
|
|
(80,309 |
) |
Net loss per ordinary
share |
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
$ |
(0.41 |
) |
|
$ |
(0.47 |
) |
|
$ |
(1.45 |
) |
|
$ |
(0.98 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NewAmsterdam Pharma Company N.V.Condensed
Consolidated Statements of Shareholders' Equity
(Deficit)(Unaudited) |
|
(In thousands of USD, except
share amounts) |
Shares |
|
|
Amount |
|
|
Additional Paid-In Capital |
|
|
Accumulated Loss |
|
|
Cumulative Translation Adjustments |
|
|
Total Shareholders' Equity |
|
Balance at December 31, 2022 |
|
81,559,780 |
|
|
|
10,055 |
|
|
|
555,625 |
|
|
|
(140,036 |
) |
|
|
4,422 |
|
|
|
430,066 |
|
Exercise of warrants |
|
208,032 |
|
|
|
27 |
|
|
|
2,671 |
|
|
|
— |
|
|
|
— |
|
|
|
2,698 |
|
Share-based compensation |
|
— |
|
|
|
— |
|
|
|
7,663 |
|
|
|
— |
|
|
|
— |
|
|
|
7,663 |
|
Total loss and comprehensive loss for the period |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(42,018 |
) |
|
|
— |
|
|
|
(42,018 |
) |
As at March 31,
2023 |
|
81,767,812 |
|
|
|
10,082 |
|
|
|
565,959 |
|
|
|
(182,054 |
) |
|
|
4,422 |
|
|
|
398,409 |
|
Exercise of warrants |
|
541,609 |
|
|
|
70 |
|
|
|
7,444 |
|
|
|
— |
|
|
|
— |
|
|
|
7,514 |
|
Exercise of stock options |
|
14,910 |
|
|
|
2 |
|
|
|
103 |
|
|
|
— |
|
|
|
— |
|
|
|
105 |
|
Share-based compensation |
|
— |
|
|
|
— |
|
|
|
5,606 |
|
|
|
— |
|
|
|
— |
|
|
|
5,606 |
|
Total loss and comprehensive loss for the period |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(38,291 |
) |
|
|
— |
|
|
|
(38,291 |
) |
As at June 30,
2023 |
|
82,324,331 |
|
|
|
10,154 |
|
|
|
579,112 |
|
|
|
(220,345 |
) |
|
|
4,422 |
|
|
|
373,343 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
December 31, 2023 |
|
82,469,768 |
|
|
|
10,173 |
|
|
|
590,771 |
|
|
|
(316,973 |
) |
|
|
4,422 |
|
|
|
288,393 |
|
Issuance of Ordinary Shares and Pre-Funded Warrants, net of
issuance costs |
|
5,871,909 |
|
|
|
759 |
|
|
|
189,207 |
|
|
|
— |
|
|
|
— |
|
|
|
189,966 |
|
Exercise of warrants |
|
926,698 |
|
|
|
121 |
|
|
|
19,674 |
|
|
|
— |
|
|
|
— |
|
|
|
19,795 |
|
Exercise of stock options |
|
452,461 |
|
|
|
60 |
|
|
|
(609 |
) |
|
|
— |
|
|
|
— |
|
|
|
(549 |
) |
Share-based compensation |
|
— |
|
|
|
— |
|
|
|
7,965 |
|
|
|
— |
|
|
|
— |
|
|
|
7,965 |
|
Total loss and comprehensive loss for the period |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(93,767 |
) |
|
|
— |
|
|
|
(93,767 |
) |
As at March 31,
2024 |
|
89,720,836 |
|
|
|
11,113 |
|
|
|
807,008 |
|
|
|
(410,740 |
) |
|
|
4,422 |
|
|
|
411,803 |
|
Exercise of warrants |
|
294,521 |
|
|
|
38 |
|
|
|
6,268 |
|
|
|
— |
|
|
|
— |
|
|
|
6,306 |
|
Share-based compensation |
|
— |
|
|
|
— |
|
|
|
8,337 |
|
|
|
— |
|
|
|
— |
|
|
|
8,337 |
|
Total loss and comprehensive loss for the period |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(39,007 |
) |
|
|
— |
|
|
|
(39,007 |
) |
As at June 30,
2024 |
|
90,015,357 |
|
|
|
11,151 |
|
|
|
821,613 |
|
|
|
(449,747 |
) |
|
|
4,422 |
|
|
|
387,439 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NewAmsterdam Pharma Company N.V.Condensed
Consolidated Statements of Cash
Flows(Unaudited) |
|
|
For the six months ended June 30, |
|
|
2024 |
|
|
2023 |
|
(In thousands of USD) |
|
|
|
|
|
Operating
activities: |
|
|
|
|
|
Loss for the period |
|
(132,774 |
) |
|
|
(80,309 |
) |
Non-cash adjustments to
reconcile loss before tax to net cash flows: |
|
|
|
|
|
Depreciation and amortization |
|
34 |
|
|
|
22 |
|
Non-cash rent expense |
|
3 |
|
|
|
3 |
|
Fair value change - derivative earnout and warrants |
|
29,258 |
|
|
|
6,525 |
|
Foreign exchange (gains)/losses |
|
3,412 |
|
|
|
(2,995 |
) |
Share-based compensation |
|
16,208 |
|
|
|
13,174 |
|
Changes in working
capital: |
|
|
|
|
|
Changes in prepayments (current and non-current) and other
receivables |
|
(8,276 |
) |
|
|
4,038 |
|
Changes in accounts payable |
|
(11,656 |
) |
|
|
1,410 |
|
Changes in accrued expenses and other current liabilities |
|
(1,110 |
) |
|
|
1,925 |
|
Changes in deferred revenue |
|
(3,680 |
) |
|
|
(4,961 |
) |
Net cash (used
in)/provided by operating activities |
|
(108,581 |
) |
|
|
(61,168 |
) |
Investing
activities: |
|
|
|
|
|
Purchase of property, plant and equipment, including internal use
software |
|
(594 |
) |
|
|
(12 |
) |
Net cash used in
investing activities |
|
(594 |
) |
|
|
(12 |
) |
Financing
activities: |
|
|
|
|
|
Proceeds from offering of Ordinary Shares and Pre-Funded
Warrants |
|
190,481 |
|
|
|
— |
|
Transaction costs on issue of Ordinary Shares and Pre-Funded
Warrants |
|
(515 |
) |
|
|
— |
|
Proceeds from exercise of warrants |
|
13,421 |
|
|
|
8,621 |
|
Proceeds from exercise of options |
|
440 |
|
|
|
105 |
|
Payment of withholding taxes related to net share settlement of
exercised options |
|
(989 |
) |
|
|
— |
|
Net cash provided by
financing activities |
|
202,838 |
|
|
|
8,726 |
|
Net change in cash |
|
93,663 |
|
|
|
(52,454 |
) |
Foreign exchange
differences |
|
(3,405 |
) |
|
|
1,432 |
|
Cash at the beginning of the
period |
|
340,450 |
|
|
|
467,728 |
|
Cash at the end of the
period |
|
430,708 |
|
|
|
416,706 |
|
Noncash financing and
investing activities |
|
|
|
|
|
Right-of-use assets obtained in exchange for new operating lease
liabilities |
|
562 |
|
|
|
— |
|
|
|
|
|
|
|
|
|
NewAmsterdam Pharma Comp... (NASDAQ:NAMS)
Historical Stock Chart
From Jul 2024 to Aug 2024
NewAmsterdam Pharma Comp... (NASDAQ:NAMS)
Historical Stock Chart
From Aug 2023 to Aug 2024